Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

NCT07531433 | Unknown

• 1 other identifier: ATH434-901
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.

Conditions

Multiple System Atrophy

Interventions

ATH434 DRUG

ATH434 tablets

Also known as: PBT434

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Completed Alterity protocol ATH434-201 or ATH434-202
• Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician

You may not qualify if:

• Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason
• Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion

Sponsors & Collaborators

• Alterity Therapeutics: lead

MeSH Terms

Conditions

Multiple System Atrophy

Interventions

ATH434; 8-hydroxyquinazolin-4(3H)-one

Condition Hierarchy (Ancestors)

Primary Dysautonomias; Autonomic Nervous System Diseases; Nervous System Diseases; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Alterity Clinical Trials

CONTACT

888-556-7582; clinicaltrials@alteritytx.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: April 15, 2026
• Last Updated: April 15, 2026

Record last verified: 2026-03